Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q9ULY5
UPID:
CLC4E_HUMAN
Alternative names:
C-type lectin superfamily member 9; Macrophage-inducible C-type lectin
Alternative UPACC:
Q9ULY5; B2R6Q6
Background:
C-type lectin domain family 4 member E, also known as Macrophage-inducible C-type lectin, plays a pivotal role in the innate immune system. It acts as a pattern recognition receptor, identifying both damage-associated molecular patterns of abnormal self and pathogen-associated molecular patterns of bacteria and fungi. This protein's ability to recognize mycobacterial trehalose 6,6'-dimycolate, a potent immunomodulatory glycolipid, and alpha-mannose residues on pathogenic fungi, underscores its significance in immune response modulation.
Therapeutic significance:
Understanding the role of C-type lectin domain family 4 member E could open doors to potential therapeutic strategies.